Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated – Oncology Nurse Advisor
Oncology Nurse Advisor |
Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
Oncology Nurse Advisor First-line pembrolizumab followed by second-line ipilimumab or first-line nivolumab followed by second-line ipilimumab are the most cost-effective, immunotherapeutic options for patients with treatment-naïve BRAF wild-type advanced melanoma, according … |
